Ouster Seeks Shareholder Approval to Double Authorized Common Stock, Enabling Significant Future Dilution

summarizeSummary

Ouster, Inc. is asking shareholders to approve a 100% increase in authorized common stock, potentially enabling significant future dilution, and to exculpate officers from certain fiduciary duty breaches.

check_boxKey Events

• Proposed Increase in Authorized Shares

  The company is seeking shareholder approval to increase the number of authorized common stock from 100,000,000 to 200,000,000 shares. This represents a 100% increase in authorized shares.

• Significant Potential Dilution

  If all 100,000,000 newly authorized shares were issued, it would represent a potential dilution of approximately 157.5% relative to the 63,461,091 shares outstanding as of March 31, 2026.

• Officer Exculpation Proposal

  Shareholders will vote on an amendment to the Certificate of Incorporation to provide for the exculpation of officers from liability for breaches of fiduciary duty of care, to the extent permitted by Delaware law.

• Director Re-election and Departure

  Phillip M. Eyler and Angus Pacala are nominated for re-election as Class II Directors. Current director Virginia Boulet has not been nominated for re-election.

auto_awesomeAnalysis

Ouster, Inc. is seeking shareholder approval for several proposals at its upcoming Annual Meeting, most notably an amendment to increase its authorized common stock from 100,000,000 to 200,000,000 shares. This substantial increase, if fully utilized, represents a potential dilution of approximately 157.5% relative to the current outstanding shares (63,461,091 as of March 31, 2026). The company states the additional shares are for broad corporate purposes including financing activities, public or private offerings, strategic relationships, and acquisitions, indicating a significant potential for future capital raises or M&A that could heavily dilute existing shareholders. Additionally, the company proposes to amend its Certificate of Incorporation to exculpate officers from liability for breaches of fiduciary duty of care, aligning officer protections with those already afforded to directors, which is a notable corporate governance change.